Market reviews 2008

Market review on human pharmaceuticals 2008

Published 6 February 2009

Finland is Orion’s most important single market area. According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesales of human pharmaceuticals in 2008 totalled EUR 1,945.2 million, up by 6.5% on the previous year. Total pharmacy sales grew by 6.9% and hospital sales by 5.5% compared with the previous year. The wholesales of prescription drugs rose by 6.8%, while the wholesales of self-care products grew by 4.2%.

Orion is still strongly positioned as the leading marketer of pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesales of human pharmaceuticals in Finland in 2008 totalled EUR 179.6 million, up by 10.4% on the previous year. The development of Orion’s sales was clearly more vigorous than the overall market growth in the segments of self-care products and prescription drugs. The main reason for Orion’s strong performance is the continuously renewed product portfolio. Orion’s market share was 9.2% (9.0%), and 1.5 percentage units higher than that of the second largest marketer.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2008 the sales of Parkinson’s disease drugs in the USA totalled USD 1,286 (1,190) million, up by 8.1% on the previous 12-month period. A year earlier, the corresponding growth rate was still about 25%. The distinct slowdown in market growth was caused by the expiry of the patent for the leading product, a dopamine agonist, and the consequent generic competition. The five largest European markets for Parkinson’s disease drugs were Germany, the UK, France, Spain and Italy. Total sales of Parkinson’s drugs in these countries in the same 12-month period totalled EUR 894 (820) million, with an average market growth of about 9.0% on the comparative period in the previous year.

 

Published 28 October 2008

Finland is the most important market area for Orion. According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesales of human pharmaceuticals in January–September 2008 totalled EUR 1,423.7 million, up by 6.4% on the comparative period last year. Total pharmacy sales grew by 6.8% and hospital sales by 5.3% on the comparative period. The wholesales of prescription drugs rose by 6.8%, whereas the wholesales of self-care products grew by only 2.9%.

Orion is still strongly positioned as the leading marketer of pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesales of pharmaceuticals in Finland in January–September 2008 totalled EUR 133.3 million, up by 9.7% on the comparative period last year. The development of Orion’s sales was clearly more vigorous than the overall market growth in the segments of pharmacy sales, self-care products and prescription drugs. The main reason for Orion’s strong performance is the continuously renewed product portfolio. Orion’s market share was 9.4% (9.0%), and nearly two percentage units higher than that of the second largest marketer.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2008 the sales of Parkinson’s disease drugs in the USA totalled USD 1,330 (1,126) million, up by 18.1% on the comparative 12-month period. These products are very important for Orion. The five largest European markets for Parkinson’s disease drugs were Germany, the UK, France, Spain and Italy. Total sales of Parkinson’s drugs in these countries in the same 12-month period totalled EUR 876 (805) million, with an average market growth of about 8.8% on the comparative period.

 

Published 5 August 2008

Finland is the most important market area for Orion. According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesales of human pharmaceuticals in the first two quarters of 2008 were EUR 952.9 (895.7) million, up by 6.3% on the comparative period last year. Pharmacy sales grew by 6.4%, and hospital sales increased almost at the same rate, growth being 6.3%. The wholesales of prescription drugs rose by 6.8%, whereas the wholesales of self-care products grew only by 2.4%. The development of Orion’s sales was clearly faster than the overall market growth in the segments of pharmacy sales, prescription drugs and self-care products.

Orion is still strongly positioned as the leading marketer of pharmaceuticals in Finland. In the first two quarters of 2008, the wholesales of Orion’s human pharmaceuticals totalled EUR 89.4 million, up 10.0% on the comparative period. The main reason for Orion’s strong performance is the continuously renewed product portfolio. Orion’s market share in the first half of 2008 was 9.4% (9.0%), and 2.0 percentage units higher than that of the second largest marketer.

Parkinson’s Disease is a vital therapy area for Orion. According to IMS Health pharmaceutical sales statistics in the 12-month period ending in March 2008, the sales of Parkinson’s Disease drugs in the USA totalled USD 1,309 (1,067) million, up by 22.8% on the comparative 12-month period. The exceptionally high growth rate is explained by the broadened indication of one dopamine agonist to the restless legs syndrome. The five largest European markets for Parkinson’s Disease drugs were Germany, UK, France, Spain and Italy. Total sales of Parkinson’s drugs in these countries in the same 12-month period totalled EUR 856 (790) million, with an average growth at 8.5%.

 

Published 25 April 2008

According to statistics for the first quarter of 2008 collected by Finnish Pharmaceutical Data Ltd, Finnish wholesales of human pharmaceuticals rose by 6.5% to EUR 471.7 (442.9) million. Hospital sales non-reimbursable medicines showed higher growth than the total average, up by 8.7% and 12.5% respectively. The wholesales of self-care products grew by 0.7%, and those of substitutable prescription medicines decreased by 0.4% from the comparative period. Orion’s own sales development was positive in these two product segments.

Orion’s position as the leading marketer of pharmaceuticals in Finland continued to be strong. In the first quarter of 2008, wholesales of Orion’s human pharmaceuticals totalled EUR 45.3 million, up 8.7% on the comparative period. The sales of self-care products and reimbursable prescription medicines developed particularly well, thereby counterbalancing their sluggish total sales in the period. Orion’s market share was further bolstered: in the first quarter it was 9.6% (9.2%), and 2.0 percentage units higher than that of the second largest marketer. On an annual level, Orion’s domestic market share continued to be 9%.

Wholesales of drugs for Parkinson’s Disease – a core therapy area for Orion – totalled USD 1,250 (1,003) million in the US in 2007, according to IMS Health pharmaceutical sales statistics, up about 24.5% on 2006. The five largest European markets for Parkinson’s Disease drugs were Germany, Great Britain, France, Spain and Italy. Total sales of Parkinson’s Disease drugs in these countries in 2007 came to EUR 842 (771) million, with an average growth of about 9.3%.